Blood cell collection could pave way for new immune therapies

NCT ID NCT04838171

Recruiting now Knowledge-focused Sponsor: Quell Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects white blood cells from up to 10 healthy volunteers and patients with autoimmune diseases, inflammation, or liver transplant. The goal is to analyze these cells to help develop engineered regulatory T cell (Treg) therapies. No treatment is given; it is a research-only study to understand white blood cell characteristics.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help create new cell therapies that control harmful immune responses in autoimmune diseases and organ transplant patients.
What could go wrong: This is a very early, small study (10 participants) focused on collecting cells for lab research, not testing a treatment. It may not lead to a working therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease Inflammation inflammatory disease Rejection, Psychology transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES INFLAMMATION REJECTION; TRANSPLANT, LIVER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Quell Investigator Site 01
RECRUITING

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.